Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Y-MABS THERAPEUTICS, INC.

(YMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Medulloblastoma Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Oncurious, Y-mAbs Therapeutics, Senhwa Biosciences, Sun Pharmaceutical, Roche and Others

06/03/2021 | 04:14am EDT

Medulloblastoma is a cancerous brain tumor that starts in the lower back part of the brain, called the cerebellum. Medulloblastoma accounts for nearly 10% of all childhood brain tumors. These tumors occur exclusively in the posterior fossa and have the potential for leptomeningeal spread. Signs and symptoms of medulloblastoma may include headaches, nausea, vomiting, tiredness, dizziness, double vision, poor coordination and unsteady walk. Medulloblastoma is diagnosed based upon thorough clinical and neurological evaluation, detection of characteristic symptoms and physical findings, patient history, and specialized diagnostic tests.

DelveInsight's, "Medulloblastoma Pipeline Insight, 2021," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Medulloblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request for free sample report: https://www.delveinsight.com/sample-request/medulloblastoma-pipeline-insight

Some of Medulloblastoma Companies are:*Oncurious *Y-mAbs Therapeutics *Senhwa Biosciences *Sun Pharmaceutical Industries *Roche *Nelum *WPD Pharmaceuticals *Midatech *Kintara Therapeutics *VBI Vaccines *Oncoheroes Biosciences *And Many Others

Request for free sample report: https://www.delveinsight.com/sample-request/medulloblastoma-pipeline-insight

DelveInsight's Medulloblastoma report covers around 12+ products under different phases of clinical development like*Late stage products (Phase III) *Mid-stage products (Phase II) *Early-stage product (Phase I) along with the details of *Pre-clinical and Discovery stage candidates *Discontinued & Inactive candidates

Some of Medulloblastoma therapies are:*TB-403 *Omburtamab-Lu-177 *Silmitasertib *Sonidegib *Vismodegib *NLM 001 *WP1066 *Panobinostat *Dianhydrogalactitol *VBI 1901 *2HIT medulloblastoma *And Many Others

Request for free sample report: https://www.delveinsight.com/sample-request/medulloblastoma-pipeline-insight

Current Medulloblastoma Treatment Scenario and Medulloblastoma Emerging Therapies:*How many companies are developing Medulloblastoma drugs? *How many Medulloblastoma drugs are developed by each company? *How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Medulloblastoma? *What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Medulloblastoma therapeutics? *What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? *What are the clinical studies going on for Medulloblastoma and their status? *What are the key designations that have been granted to the emerging drugs?

Table of Contents:

Introduction

Executive Summary

Medulloblastoma: Overview

Pipeline Therapeutics

* Comparative Analysis

Therapeutic Assessment

Medulloblastoma - DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Medulloblastoma Collaboration Deals

Late Stage Products (Phase III)

* Comparative Analysis

Drug name: Company name

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

* Comparative Analysis

Vismodegib: Roche

Drug profiles in the detailed report.....

Early Stage Products (Phase I/II)

* Comparative Analysis

Omburtamab-Lu-177: Y-mAbs Therapeutics

Drug profiles in the detailed report.....

Preclinical and Discovery Stage Products

* Comparative Analysis

Dianhydrogalactitol: Kintara Therapeutics

Drug profiles in the detailed report.....

Inactive Products

Medulloblastoma Key Companies

Medulloblastoma Key Products

Medulloblastoma- Unmet Needs

Medulloblastoma- Market Drivers and Barriers

Medulloblastoma- Future Perspectives and Conclusion

Medulloblastoma Analyst Views

Medulloblastoma Key Companies

Appendix

Request for Detailed TOC: https://www.delveinsight.com/sample-request/medulloblastoma-pipeline-insight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

Address:304 S. Jones Blvd #2432

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com/report-store/medulloblastoma-pipeline-insight

Source: www.abnewswire.com

.

(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
KINTARA THERAPEUTICS, INC. 1.74% 0.8926 Delayed Quote.-31.25%
ROCHE HOLDING AG -0.68% 338.5 Delayed Quote.10.16%
SENHWA BIOSCIENCES, INC. -0.35% 143.5 End-of-day quote.-36.22%
SUN PHARMACEUTICAL INDUSTRIES LTD. -0.96% 763.05 Delayed Quote.30.07%
Y-MABS THERAPEUTICS, INC. 2.65% 29.36 Delayed Quote.-42.03%
All news about Y-MABS THERAPEUTICS, INC.
09/23INSIDER SELL : Y-mabs Therapeutics
MT
09/16Y MABS THERAPEUTICS : mAbs Announces Data to be Presented at SIOP 2021
AQ
09/14Y MABS THERAPEUTICS : mAbs Announces Priorit Review of BLA for DANELZA (naxitamab-gqgk) in..
AQ
09/13Y MABS THERAPEUTICS : mAbs-Licensed Danelza Granted Priorit Review b Chinese Regulator; Sh..
MT
09/13Y MABS THERAPEUTICS : mAbs Announces Priorit Review of BLA for DANELZA« (naxitamab-gqgk) i..
PU
09/13Y MABS THERAPEUTICS : mAbs to Host Ke Opinion Leader Webinar on DANELZA (naxitamab-gqgk) F..
AQ
09/13Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/13Y MABS THERAPEUTICS : mAbs Announces Priorit Review of BLA for DANELZA« (naxitamab-gqgk) i..
AQ
09/13Y-Mabs Therapeutics, Inc. Announces Priority Review of BLA for DANYELZA« (Naxitamab-Gqg..
CI
09/10Y MABS THERAPEUTICS : mAbs to Host Ke Opinion Leader Webinar on DANELZA« (naxitamab-gqgk) ..
AQ
More news
Analyst Recommendations on Y-MABS THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 71,5 M - -
Net income 2021 -42,6 M - -
Net cash 2021 83,9 M - -
P/E ratio 2021 -33,3x
Yield 2021 -
Capitalization 1 251 M 1 251 M -
EV / Sales 2021 16,3x
EV / Sales 2022 7,52x
Nbr of Employees 125
Free-Float 83,7%
Chart Y-MABS THERAPEUTICS, INC.
Duration : Period :
Y-mAbs Therapeutics, Inc. Technical Analysis Chart | YMAB | US9842411095 | MarketScreener
Technical analysis trends Y-MABS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 28,70 $
Average target price 55,33 $
Spread / Average Target 92,8%
EPS Revisions
Managers and Directors
Claus Juan M°ller-San Pedro Chief Executive Officer & Director
Thomas Gad Chairman, President & Head-Business Development
Bo Kruse CFO, Secretary. Treasurer & Executive VP
Torben Lund-Hansen Chief Technology Officer & Senior Vice President
Steen Lisby Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
Y-MABS THERAPEUTICS, INC.-42.03%1 251
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
REGENERON PHARMACEUTICALS32.25%66 425
WUXI APPTEC CO., LTD.34.39%59 817
VERTEX PHARMACEUTICALS-22.31%47 634